Gilead Withdraws Request for Special Orphan Status on Experimental Virus Treatment by BY KATIE THOMAS

Critics said the company was profiteering from the coronavirus pandemic by seeking tax and monopoly benefits under a program intended to encourage drug development for rare diseases.

Published: March 25, 2020 at 07:13PM

from NYT Health